Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite the development of multimodal therapy. Expression of glypican-1 (GPC1) has been reported to be elevated in a subset of patients with ESCC and associated with chemoresistance. This study aimed to determine the association of GPC1...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Emi, Serada, Satoshi, Fujimoto, Minoru, Takahashi, Yusuke, Takahashi, Tsuyoshi, Hara, Hisashi, Nakatsuka, Rie, Sugase, Takahito, Nishigaki, Takahiko, Saito, Yurina, Hiramatsu, Kosuke, Nojima, Satoshi, Mitsuo, Risa, Ohkawara, Tomoharu, Morii, Eiichi, Mori, Masaki, Doki, Yuichiro, Kaneda, Yasufumi, Naka, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421884/
https://www.ncbi.nlm.nih.gov/pubmed/28445969
http://dx.doi.org/10.18632/oncotarget.15799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421884/
https://www.ncbi.nlm.nih.gov/pubmed/28445969
http://dx.doi.org/10.18632/oncotarget.15799

Ejemplares similares